Engineering Strategies to Overcome the Current Roadblocks in CAR T Cell Therapy

Various barriers restrict the efficacy and/or prevent the widespread use of CAR T cell therapies. Key challenges include severe toxicities, restricted trafficking to, infiltration into, and activation within tumors, suboptimal persistence in vivo, antigen escape and heterogeneity, and manufacturing issues. The authors discuss novel CAR T cell products being developed to expand the clinical benefits of these treatments.